Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy

Table 1

Demographic, immunological and virological data for the cases described.

No.	Year	Age	Sex	Race	HIV diagnosis	HAART start	Baseline CD4 count (cells/μL)	CD4 count at symptoms (cells/μL)	HIV RNA change (copies/mL)	HAART regimen
(1)	2003	34	M	African; American	March 1993	June 1999	59	341	>750,000 to 775	Stavudine
										Abacavir
										Lamivudine
										Efavirenz
(2)	2007	42	M	African; American	December 2002	December 2002	89	537	205 to <50	Lamivudine
										Zidovudine
										Efavirenz
(3)	2007	39	M	African	April 2005	April 2005	59	250	<50 to <50	Tenofovir
										Emtricitabine
										Efavirenz
										Tenofovir
(4)	2008	43	F	African; American	March 2006	October 2006	29	462	252,984 to <50	Emtricitabine
										Efavirenz